Weekly Alendronate versus Zoledronic Acid For Prevention of Bone Loss During the First Year After Heart or Liver Transplantation

Trial Profile

Weekly Alendronate versus Zoledronic Acid For Prevention of Bone Loss During the First Year After Heart or Liver Transplantation

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2011

At a glance

  • Drugs Alendronic acid (Primary) ; Zoledronic acid (Primary)
  • Indications Bone resorption; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2011 Results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
    • 13 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top